Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 16/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 16/20 | 0.60 |
| ▸ | SHBG | P04278 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3927613 | 0.86 | ESR1 (0.67) | ESR1ESR2SHBG | |
| SCHEMBL13980531 | 0.78 | ESR1 (0.57) | ESR1ESR2SHBG | |
| SCHEMBL4068292 | 0.77 | EGFR (0.43) | ESR1ESR2 | |
| SCHEMBL3924007 | 0.76 | ESR1 (0.60) | ESR1ESR2SHBG | |
| SCHEMBL5913544 | 0.76 | ESR1 (1.00) | ESR1ESR2SHBG | |
| SCHEMBL1119325 | 0.73 | ESR1 (1.00) | ESR1ESR2SHBG | |
| SCHEMBL3922882 | 0.73 | ESR2 (0.76) | ESR1ESR2SHBG | |
| SCHEMBL31042796 | 0.72 | ESR2 (1.00) | ESR1ESR2SHBG | |
| SCHEMBL3925053 | 0.72 | ESR2 (1.00) | ESR1ESR2SHBG | |
| SCHEMBL13980511 | 0.70 | ESR1 (0.61) | ESR1ESR2SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009009417-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-15 | — | — | WO | claimed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | claimed |
| EP-1458700-B1 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | WYETH CORP (US) | 2008-12-03 | — | — | EP | claimed |
| EP-1458700-A2 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-22 | — | — | EP | claimed |
| US-6774248-B2 | ANTICANCER AGENTS; ANTICHOLESTEROL AGENTS; COGNITION ACTIVATORS; RHEUMATIC DISEASES | WYETH | 2004-08-10 | — | — | US | claimed |
| US-20030171428-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH | 2003-09-11 | — | — | US | claimed |
| WO-2003051860-A2 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-26 | — | — | WO | claimed |
| WO-2009009417-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| EP-1458700-B1 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | WYETH CORP (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20060074128-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH (US) | 2006-04-06 | — | — | US | disclosed |
| US-7022733-B2 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| US-20050038107-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH | 2005-02-17 | — | — | US | disclosed |
| EP-1458700-A2 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-22 | — | — | EP | disclosed |
| US-6774248-B2 | ANTICANCER AGENTS; ANTICHOLESTEROL AGENTS; COGNITION ACTIVATORS; RHEUMATIC DISEASES | WYETH | 2004-08-10 | — | — | US | disclosed |
| US-20030171428-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH | 2003-09-11 | — | — | US | disclosed |
| WO-2003051860-A2 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074128-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | ESR1, ESR2, GPER1 | ESR1 1/4885ESR2 2/4885SHBG 22/4885 |
| US-20050038107-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | ESR1, ESR2, ESRRA | ESR1 1/4885ESR2 2/4885SHBG 16/4885 |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | COL2A1, COL1A1, COL14A1 | ESR1 4/4885ESR2 5/4885SHBG 6/4885 |
| US-20030171428-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | ESR1, ESR2, GPER1 | ESR1 1/4885ESR2 2/4885SHBG 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.